Method and reagent for treatment of diseases caused by expression of the c-myc gene

Abstract

The present invention relates to an enzymatic RNA molecule which cleaves mRNA derived from c-myc gene.

Description

[0001] This patent application is a continuation of Thompson, U.S. Ser. No. 08 / 192,943 filed Feb. 7, 1994, which is a continuation of Thompson, U.S. Ser. No. 07 / 936,422 filed Aug. 26, 1992, abandoned, all entitled "METHOD AND REAGENT FOR TREATMENT OF DISEASES CAUSED BY EXPRESSION OF THE c-MYC GENE". All of the above applications are hereby incorporated by reference herein in their entirety, including the drawings.BACKGROUND OF THE INVENTION[0002] This invention relates to methods for inhibition of growth of transformed cells, and inhibition of progression to a transformed phenotype in pre-neoplastic cells.[0003] Transformation is a cumulative process whereby normal control of cell growth and differentiation is interrupted, usually through the accumulation of mutations affecting the expression of genes that regulate cell growth and differentiation.[0004] Scanlon W091 / 18625, W091 / 18624, and W091 / 18913 describes a ribozyme effective to cleave oncogene RNA from the H-ras gene. This ribo...

AI Technical Summary

Benefits of technology

0020] The invention provides a class of chemical cleaving agents which exhibit a high degree of specificity for the mRNA causative of Burkitt's lymphoma or acute lymphocytic leukemia. Such enzymatic RNA molecules can be delivered exogenously or endogenously to infected cells. In the preferred hammerhead motif the small size (less than 40 nucleotides, preferably between 32 and 36 nucleotides in length) of the molecule allows the cost of treatment to be reduced.

0021] The smallest ribozyme delivered for any type of treatment reported to date (by Rossi et al., 1992 supra) is an in vitro transcript having a length of 142 nucleotides. Synthesis of ribozymes greater than 100 nucleotides in length is very difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. Delivery of ribozymes by expression vectors is primarily feasible using only ex vivo treatments. This limits the utility of this approach. In this invention, an alternative approach uses smaller ribozyme motifs (e.g., of the hammerhead structure, shown generally in FIG. 1) and exogenous delivery. The simple structure of these molecules also increases the ability of the ribozyme to invade targeted regions of the mRNA structure. Thus, unlike the situation when the hammerhead structure is included within longer transcripts, there are no non-ribozyme flanking sequences to interfere with correct folding of the ribozyme structure, as well as complementary binding of the ribozyme to the mRNA target.

0022] The enzymatic RNA molecules of this invention can be used to treat human Burkitt's lymphoma, acute lymphocytic leukemia or precancerous conditions. Such treatment can also be extended to other related genes in nonhuman primates. Affected animals can be treated at the time of cancer detection or in a prophylactic manner. This timing of treatment will reduce the number of affected cells and disable cellular replication. This is possible because the ribozymes are designed to disable those structures required for successful cellular proliferation.

Problems solved by technology

Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein.

Images